VTYX Q2 2024 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$316,000

Operating Income

-$36M

Net Income

-$32M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$309M

Total Liabilities

$28M

Stockholders' Equity

$281M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$316,000	$0	—
Operating Income	-$36M	-$57M	+37.5%
Net Income	-$32M	-$53M	+40.0%